Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma

NEXT STORY
BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones
PREV STORY
ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ocera Appoints Dr. Stan Bukofzer as Chief Medical Officer

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News

Humanigen CEO to Present at Inaugural LD Micro Virtual Conference

BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress

STAMFORD, Conn., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

author_avatar
NASDAQ Market News